Study of YL217 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests an experimental drug called YL217 in people with advanced solid tumors that have not responded to other treatments. The drug may work by targeting a protein on cancer cells and delivering a chemotherapy-like agent directly to the tumor, potentially slowing or stopping its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor (such as colorectal cancer) that cannot be removed by surgery or has spread.
- You are generally able to care for yourself (performance status 0 or 1).
- You have at least one measurable tumor outside the brain that can be checked with imaging.
- You have a stored tumor tissue sample from an earlier biopsy.
- You have not had certain prior treatments, including drugs that target CDH17 or certain types of chemotherapy (topoisomerase I inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called YL242 in people with advanced solid tumors that have not responded to prior treatment or have not been treated yet. It looks at safety, how well the drug works, and includes different groups based on cancer type and prior therapy.
This trial tests YL201 in people with advanced (late-stage) solid cancers when usual treatments don’t work or can’t be tolerated. The study looks at how the treatment is given, how safe it is, and how well it can shrink tumors.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two new drugs (QLS31905 and/or QL1706) with chemotherapy for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.